Abstract:Background: Tumor lysis syndrome (TLS) is recognized as an oncologic disorder with a variable incidence. TLS can cause the rapid destruction of tumor cells in response to oncologic therapy and is characterized by multiple electrolyte disturbances as well as its secondary complications, including death. This disease is common among patients with hematologic neoplasms, but very rare among those with solid tumors, as is the case with sarcomas. Such patients have a poor prognosis and increased risk of mortality. In the patient's particular case, this occurred after initiating third-line systemic therapy with gemcitabine associated with pazopanib, an event not previously described in the literature. Case description: We report the case of a patient with a history of high-grade sarcoma of the left lower limb T4N1M0 stage IIIB undergoing surgical management and exhibiting tumor progression with the need for third-line systemic therapy with pazopanib and gemcitabine. The patient presented with pain at the amputation site, inflammatory changes, and a tumor mass of large components on admission. They later developed electrolyte imbalance and acute renal injury compatible with TLS after systemic therapy was initiated. Pharmacological therapy, including rasburicase, was initiated based on the clinical and laboratory findings. Due to the progression of renal involvement, it was necessary to initiate haemodialysis, and during her hospital stay, the patient presented febrile syndrome associated with pancytopenia. The patient showed a favourable clinical response to the proposed antibiotic therapy and recovery of renal function, for which reason therapy was restarted with pazopanib and gemcitabine, the latter with a 20% reduction for the following cycles. Outpatient follow-up continued, completing eight cycles of treatment with good tolerance and partial clinical response; the patient died of respiratory complications eight months after discharge. Conclusions: There is limited evidence for TLS in patients with high-grade sarcoma in the literature related to the oncologic therapy used; this indicates that early risk evaluation along with prompt initiation of effective therapies is required to prevent the appearance of this type of complications in the short and long term.

Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases

Carfilzomib induced cardiotoxicity in a multiple myeloma patient

Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma

Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.

Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy

Bcma car-t治疗后复发/难治多发性骨髓瘤患者发生肿瘤溶解综合征的危险因素分析

Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.

Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review

Hypercalcemia-Driven Spontaneous Tumor Lysis Syndrome in a Case of Recently Diagnosed Multiple Myeloma: An Unusual Clinical Encounter

Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes

Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple Myeloma: A Meta-Analysis of Data from Clinical Trials

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China

Carfilzomib inhibits the proliferation and apoptosis of multiple myeloma cells by inhibiting STAT1/COX-2/iNOS signaling pathway

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis

First case report of tumor lysis syndrome after third line systemic therapy with gemcitabine and pazopanib in a patient with lower extremity soft tissue sarcoma

Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database

Carfilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)

Efficacy and Toxicity of Carfilzomib- or Bortezomib-Based Regimens for Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma